{
"info": {
"nct_id": "NCT01703091",
"official_title": "A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy",
"inclusion_criteria": "* Non-Small Cell Lung Cancer disease\n* Clinical stage IV or recurrent disease\n* One prior first-line platinum-based chemotherapy regimen with or without maintenance therapy\n* For Non-Small Cell Lung Cancer (NSCLC) tumors other than squamous cell histology, the epidermal growth factor receptor (EGFR) mutation status is known prior to randomization\n* For participants with activating epidermal growth factor receptor (EGFR) mutation only, prior epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) monotherapy (only one regimen in the setting of single use) should be utilized\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1\n* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version RECIST version 1.1\n* Adequate organ function\n* Estimated life expectancy of at least 3 months.\nHealthy volunteers allowed\nMust have minimum age of 20 Years",
"exclusion_criteria": "* Have undergone major surgery within 28 days prior to randomization or have planned major surgery during study treatment\n* Receiving concurrent treatment with other anticancer therapy\n* Central nervous system disease other than stable and treated brain metastasis\n* Has major blood vessel invasion or encasement by cancer\n* Has intratumor cavitation\n* Has a history of uncontrolled thrombotic disorder\n* Is receiving therapeutic anticoagulation with drugs\n* Is receiving chronic therapy with nonsteroidal anti-inflammatory drugs\n* Has a history of hemoptysis within 2 months prior to randomization\n* Has clinically relevant congestive heart failure\n* Has experienced any arterial thromboembolic event\n* Has uncontrolled arterial hypertension\n* Has had a serious or nonhealing wound or, ulcer\n* Has significant existing conditions",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Non-Small Cell Lung Cancer disease",
"criterions": [
{
"exact_snippets": "Non-Small Cell Lung Cancer",
"criterion": "Non-Small Cell Lung Cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Clinical stage IV or recurrent disease",
"criterions": [
{
"exact_snippets": "Clinical stage IV",
"criterion": "clinical stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "IV"
}
]
},
{
"exact_snippets": "recurrent disease",
"criterion": "disease recurrence",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* One prior first-line platinum-based chemotherapy regimen with or without maintenance therapy",
"criterions": [
{
"exact_snippets": "One prior first-line platinum-based chemotherapy regimen",
"criterion": "prior chemotherapy regimen",
"requirements": [
{
"requirement_type": "type",
"expected_value": "platinum-based"
},
{
"requirement_type": "line",
"expected_value": "first-line"
},
{
"requirement_type": "quantity",
"expected_value": true
}
]
},
{
"exact_snippets": "with or without maintenance therapy",
"criterion": "maintenance therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "optional"
}
]
}
]
},
{
"line": "* For Non-Small Cell Lung Cancer (NSCLC) tumors other than squamous cell histology, the epidermal growth factor receptor (EGFR) mutation status is known prior to randomization",
"criterions": [
{
"exact_snippets": "Non-Small Cell Lung Cancer (NSCLC) tumors other than squamous cell histology",
"criterion": "NSCLC tumor histology",
"requirements": [
{
"requirement_type": "type",
"expected_value": "non-squamous"
}
]
},
{
"exact_snippets": "epidermal growth factor receptor (EGFR) mutation status is known prior to randomization",
"criterion": "EGFR mutation status",
"requirements": [
{
"requirement_type": "knowledge",
"expected_value": true
}
]
}
]
},
{
"line": "* For participants with activating epidermal growth factor receptor (EGFR) mutation only, prior epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) monotherapy (only one regimen in the setting of single use) should be utilized",
"criterions": [
{
"exact_snippets": "activating epidermal growth factor receptor (EGFR) mutation",
"criterion": "EGFR mutation",
"requirements": [
{
"requirement_type": "type",
"expected_value": "activating"
}
]
},
{
"exact_snippets": "prior epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) monotherapy",
"criterion": "EGFR-TKI monotherapy",
"requirements": [
{
"requirement_type": "prior treatment",
"expected_value": true
}
]
},
{
"exact_snippets": "only one regimen in the setting of single use",
"criterion": "EGFR-TKI monotherapy regimen",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "=",
"value": 1,
"unit": "regimen"
}
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1",
"criterion": "ECOG Performance Status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version RECIST version 1.1",
"criterions": [
{
"exact_snippets": "Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version RECIST version 1.1",
"criterion": "measurable disease",
"requirements": [
{
"requirement_type": "definition",
"expected_value": "Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1"
}
]
}
]
},
{
"line": "* Adequate organ function",
"criterions": [
{
"exact_snippets": "Adequate organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Estimated life expectancy of at least 3 months.",
"criterions": [
{
"exact_snippets": "Estimated life expectancy of at least 3 months.",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 20 Years",
"criterions": [
{
"exact_snippets": "minimum age of 20 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 20,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Have undergone major surgery within 28 days prior to randomization or have planned major surgery during study treatment",
"criterions": [
{
"exact_snippets": "Have undergone major surgery within 28 days prior to randomization",
"criterion": "major surgery",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<=",
"value": 28,
"unit": "days"
}
}
]
},
{
"exact_snippets": "have planned major surgery during study treatment",
"criterion": "planned major surgery",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "during study treatment"
}
]
}
]
},
{
"line": "* Receiving concurrent treatment with other anticancer therapy",
"criterions": [
{
"exact_snippets": "Receiving concurrent treatment with other anticancer therapy",
"criterion": "concurrent anticancer therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Central nervous system disease other than stable and treated brain metastasis",
"criterions": [
{
"exact_snippets": "Central nervous system disease other than stable and treated brain metastasis",
"criterion": "central nervous system disease",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": "other than stable and treated brain metastasis"
}
]
}
]
},
{
"line": "* Has major blood vessel invasion or encasement by cancer",
"criterions": [
{
"exact_snippets": "major blood vessel invasion",
"criterion": "major blood vessel invasion",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "encasement by cancer",
"criterion": "encasement by cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has intratumor cavitation",
"criterions": [
{
"exact_snippets": "Has intratumor cavitation",
"criterion": "intratumor cavitation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has a history of uncontrolled thrombotic disorder",
"criterions": [
{
"exact_snippets": "history of uncontrolled thrombotic disorder",
"criterion": "thrombotic disorder",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "uncontrolled"
}
]
}
]
},
{
"line": "* Is receiving therapeutic anticoagulation with drugs",
"criterions": [
{
"exact_snippets": "receiving therapeutic anticoagulation with drugs",
"criterion": "therapeutic anticoagulation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Is receiving chronic therapy with nonsteroidal anti-inflammatory drugs",
"criterions": [
{
"exact_snippets": "receiving chronic therapy with nonsteroidal anti-inflammatory drugs",
"criterion": "chronic therapy with nonsteroidal anti-inflammatory drugs",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has a history of hemoptysis within 2 months prior to randomization",
"criterions": [
{
"exact_snippets": "history of hemoptysis within 2 months prior to randomization",
"criterion": "history of hemoptysis",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": "within 2 months prior to randomization"
}
]
}
]
},
{
"line": "* Has clinically relevant congestive heart failure",
"criterions": [
{
"exact_snippets": "clinically relevant congestive heart failure",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "clinical relevance",
"expected_value": true
}
]
}
]
},
{
"line": "* Has experienced any arterial thromboembolic event",
"criterions": [
{
"exact_snippets": "Has experienced any arterial thromboembolic event",
"criterion": "arterial thromboembolic event",
"requirements": [
{
"requirement_type": "experience",
"expected_value": true
}
]
}
]
},
{
"line": "* Has uncontrolled arterial hypertension",
"criterions": [
{
"exact_snippets": "uncontrolled arterial hypertension",
"criterion": "arterial hypertension",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
}
]
},
{
"line": "* Has had a serious or nonhealing wound or, ulcer",
"criterions": [
{
"exact_snippets": "serious or nonhealing wound",
"criterion": "wound",
"requirements": [
{
"requirement_type": "healing status",
"expected_value": [
"serious",
"nonhealing"
]
}
]
},
{
"exact_snippets": "ulcer",
"criterion": "ulcer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has significant existing conditions",
"criterions": [
{
"exact_snippets": "significant existing conditions",
"criterion": "existing conditions",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "significant"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}